Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study describes three cases where patients with recalcitrant alopecia areata achieved complete hair regrowth on the scalp after treatment with upadacitinib, suggesting it may be beneficial for similar cases, especially those with comorbid atopic dermatitis.

ASLAN004 was safe and well-tolerated, supporting further development for treating certain diseases.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

Adalimumab significantly improves quality of life for patients with moderate to severe hidradenitis suppurativa.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This case study reported a 49-year-old woman with metastatic adrenocortical carcinoma who experienced an abscopal effect after pulse electric field ablation, leading to the resolution of three untreated liver lesions, suggesting potential benefits of this treatment combined with immunotherapy.

This study found that Imuvert consistently protected against alopecia induced by certain chemotherapy drugs in rats, potentially mediated by a monocyte-derived cytokine like interleukin-1.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

This report discusses two patients with plaque psoriasis who developed hypertrichosis, or excessive hair growth, while undergoing interleukin-17A inhibitor therapy.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This report observed that a patient with alopecia areata, resistant to ritlecitinib, experienced significant recovery after 24 weeks of treatment with upadacitinib, highlighting its potential in treating ritlecitinib-resistant cases and suggesting personalized treatment strategies in managing alopecia areata.

This article addresses the pathogenesis of alopecia areata and discusses the emerging role of oral and topical JAK inhibitors in its treatment, but reports no new clinical findings.

In this case report, a 30-year-old woman with myasthenia gravis developed vitiligo and alopecia universalis during long-term rituximab therapy. Discontinuation of rituximab and initiation of oral baricitinib led to improvement in skin conditions, underscoring potential immune-related skin effects from rituximab.

This study observed that in a real-world clinical setting in Greece, belimumab effectively controlled disease activity in lupus patients and allowed for a reduction in glucocorticoid dosage, with more pronounced benefits seen in patients who were serologically active at the start of treatment.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

In this case study, a 34-year-old woman with a rare presentation of pilomatrixoma involving alopecia and skin hypopigmentation showed no improvement in these symptoms despite a 3-month trial of topical steroid treatment, highlighting a potential association between pilomatrixoma and microinflammation.

This study found that Janus kinase inhibitors were effective in inducing clinical and biochemical remission in patients with Ulcerative Colitis while exhibiting an expected safety profile, though 30% discontinued treatment due to adverse events or lack of efficacy.

This review discusses the potential of dupilumab for treating alopecia areata, reporting mixed outcomes with both improvement and new-onset hair loss observed in case reports.

This study found that mycophenolate mofetil was well tolerated and effective as a second-line treatment for autoimmune hepatitis in patients who were intolerant to azathioprine.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

This report discusses a case of vesiculopustular eruption in a patient with ulcerative colitis, highlighting the effective use of ustekinumab for treatment and suggesting its consideration in similar cases of IBD-related skin lesions.

In this case report, a patient with Crohn's disease experienced alopecia and psoriasiform reactions attributed to anti-TNF therapy, which improved after switching to Ustekinumab.

This study found that pimecrolimus enhances melanin synthesis and promotes melanocyte migration, possibly by increasing MITF protein expression, which may explain its effectiveness in repigmenting vitiligo.

This review discusses the role of the JAK-STAT pathway in autoimmune skin diseases and suggests potential therapeutic benefits of JAK inhibitors, but reports no new experimental results.

This study observed that apremilast treatment improved skin lesions and reduced pruritus in patients with chronic, severe atopic dermatitis and one case of hand and foot dermatitis.

This study found that tralokinumab effectively reduced the severity of moderate-to-severe atopic dermatitis over 28 weeks in adults, with significant improvements in clinical outcomes and biological markers, although 27.4% of patients discontinued treatment due to adverse events or ineffectiveness.

This case report describes a 21-year-old woman with progressive alopecia areata who experienced hair regrowth while treated with tocilizumab for posterior uveitis, suggesting the potential for this drug to affect hair loss and regrowth by disrupting interleukin-6 signaling.

This review discusses the immunological basis and development of Janus kinase inhibitors for treating skin diseases and reports no new clinical findings.

In this study, induction nab-paclitaxel plus cisplatin, combined with nimotuzumab and IMRT, followed by S-1 adjuvant chemotherapy, showed excellent survival benefits with tolerable toxicities for stage N3 nasopharyngeal carcinoma patients.